Indication
CNV
2 clinical trials
3 products
Clinical trial
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)Status: Recruiting, Estimated PCD: 2025-05-01
Product
RGX-314Product
RanibizumabClinical trial
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMDStatus: Recruiting, Estimated PCD: 2025-02-01
Product
Aflibercept